Page 3 - பணக்காரர் ஹெல்ம் உயிரியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பணக்காரர் ஹெல்ம் உயிரியல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பணக்காரர் ஹெல்ம் உயிரியல் Today - Breaking & Trending Today

INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine

Trial for
Efficacy), evaluating INO-4800, its DNA vaccine candidate for COVID-19. Preliminary results show in a larger population that INO-4800 was generally safe, well-tolerated and immunogenic in all studied age groups.
Findings from the Phase 2 Clinical Trial:
The Phase 2 segment of the trial enrolled approximately 400 participants, 18 years of age or older, at 16 U.S. sites.
Participants received either INO-4800 (1.0 mg or 2.0 mg dose) or placebo at 0 and 4 weeks (randomized 3:3:1:1). Each dose was administered by intradermal injection followed by electroporation using INOVIO s CELLECTRA
®, its proprietary smart device.
Safety endpoints included systemic and local administration site reactions through 8 weeks post-dose one (or 4 weeks post-dose 2). Immunology endpoints included antigen-specific binding antibody titers, neutralization titers, and antigen-specific interferon-gamma (IFN-γ) cellular immune responses after two doses of the vaccine. ....

South Korea , Laurentm Humeau , Ben Matone , Pablo Tebas , Jeff Richardson , Kaneka Eurogentec , Walter Reed Army Institute Of Research , Us Department Of Defense , National Cancer Institute , Department Of Defense , National Institute Of Allergy , Plumbline Life Sciences , Melinda Gates Foundation , Coalition For Epidemic Preparedness Innovations , Hospital Of The University Pennsylvania , International Vaccine Institute , Defense Consortium , Parker Institute For Cancer Immunotherapy , Nuclear Defense , Defense Health Agency , National Institutes Of Health , Drug Administration , Program Executive Office For Chemical , Health Affairs , Apollobio Corporation , Vaccines Trial Network ,

INOVIO to Report First Quarter 2021 Financial Results on May 10, 2021

INOVIO to Report First Quarter 2021 Financial Results on May 10, 2021
News provided by
Share this article
Share this article
PLYMOUTH MEETING, Pa., April 27, 2021 /PRNewswire/ INOVIO (NASDAQ: INO) announced today that first quarter 2021 financial results will be released after the market close on May 10, 2021. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update regarding its DNA Medicines Platform, including the company s ongoing vaccine developments for COVID-19.
A live and archived version of the audio presentation will be available online at http://ir.inovio.com/events-and-presentations/default.aspx. This is a listen-only event but will include a live Q&A with analysts. ....

Ben Matone , Jeff Richardson , Kaneka Eurogentec , Walter Reed Army Institute Of Research , National Cancer Institute , National Institute Of Allergy , Plumbline Life Sciences , Melinda Gates Foundation , Coalition For Epidemic Preparedness Innovations , International Vaccine Institute , Defense Consortium , Pharmaceuticals Inc , Parker Institute For Cancer Immunotherapy , Nuclear Defense , Department Of Defense Do , National Institutes Of Health , Program Executive Office For Chemical , Apollobio Corporation , Vaccines Trial Network , Defense Advanced Research Projects Agency , University Of Pennsylvania , Wistar Institute , Epidemic Preparedness Innovations , Joint Program Executive Office , Trial Network , National Institutes ,

INOVIO Planning for ex-US Global Phase 3 Trial for INO-4800

Share this article
Share this article
PLYMOUTH MEETING, Pa., April 23, 2021 /PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it is planning for a predominantly ex-U.S. Phase 3 trial for its COVID-19 vaccine candidate, INO-4800. Given the increasing availability of vaccines authorized for emergency use, the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in coordination with the Office of the Assistant Secretary of Defense for Health Affairs (OASD(HA)) and the Defense Health Agency (DHA), will discontinue funding for the Phase 3 segment of the INNOVATE trial, while continuing to fund the completion of the ongoing Phase 2 segment. In correspondence, JPEO informed INOVIO: The decision results from the changing enviro ....

Ben Matone , Jeff Richardson , Kaneka Eurogentec , Walter Reed Army Institute Of Research , Us Department Of Defense , National Cancer Institute , National Institute Of Allergy , Plumbline Life Sciences , Melinda Gates Foundation , Coalition For Epidemic Preparedness Innovations , International Vaccine Institute , Defense Consortium , Parker Institute For Cancer Immunotherapy , Nuclear Defense , Department Of Defense Do , Defense Health Agency , National Institutes Of Health , Program Executive Office For Chemical , Health Affairs , Apollobio Corporation , Vaccines Trial Network , Defense Advanced Research Projects Agency , Office Of The , University Of Pennsylvania , Wistar Institute , Defense Joint Program Executive Office ,

The global vaccine contract manufacturing market by revenue is expected to grow at a CAGR of approx. 13% during the period 2020–2026

The global vaccine contract manufacturing market by revenue is expected to grow at a CAGR of approx. 13% during the period 2020–2026
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Vaccine Contract Manufacturing Market Report. The global vaccine contract manufacturing market by revenue is expected to grow at a CAGR of approx.
April 16, 2021 09:32 ET
| Source:
ReportLinker
ReportLinker
Lyon, FRANCE
New York, April 16, 2021 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report Vaccine Contract Manufacturing Market - Global Outlook and Forecast 2021-2026 - https://www.reportlinker.com/p06063357/?utm source=GNW
13% during the period 2020–2026.
The global vaccine contract manufacturing market has experienced radical transformations after the outbreak of the COVID-19 pandemic, which has been a massive health catastrop ....

New York , United States , United Kingdom , South Africa , Saudi Arabia , South Korea , Cytovance Biologics , Therapure Biopharma , Samsung Biologics , Ajinomoto Bio Pharma , Cerbios Pharma , Axcellerate Pharma , Kaneka Eurogentec , Corden Pharma , Eden Biologics , Kemwell Biopharma , Boehringer Ingelheim , Pharmaceutics International Inc , Baxter Biopharma Solutions , Albany Molecular Research , Merck Kga , Serum Institute Of India , Siegfried Holding , Vaccine Developers , Taron Solutions , Albany Molecular Research Institute ,

CEPI partner INOVIO launches Lassa vaccine Phase I trial in West Africa

CEPI partner INOVIO launches Lassa vaccine Phase I trial in West Africa
ghanavisions.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ghanavisions.com Daily Mail and Mail on Sunday newspapers.

Ben Matone , Jeff Richardson , Kaneka Eurogentec , Kwadwoa Koram , Walter Reed Army Institute Of Research , Us Department Of Defense , National Cancer Institute , Noguchi Memorial Institute For Medical Research , National Institute Of Allergy , Plumbline Life Sciences , Melinda Gates Foundation , Coalition For Epidemic Preparedness Innovations , International Vaccine Institute , Defense Consortium , Parker Institute For Cancer Immunotherapy , Nuclear Defense , Department Of Defense Do , National Institutes Of Health , Program Executive Office For Chemical , Apollobio Corporation , Vaccines Trial Network , Defense Advanced Research Projects Agency , University Of Pennsylvania , Wistar Institute , Clinical Trial , Noguchi Memorial Institute ,